Beryl Drugs Ltd

Beryl Drugs has announced its financial results for the quarter ending February 2025, showing consistent performance with stable key financial metrics. The company's evaluation remains unchanged, indicating a period of consolidation in its financial outlook amidst the complexities of the pharmaceutical sector.

Beryl Drugs, a microcap pharmaceutical company, reported flat financial performance in the second quarter of fiscal year 2024-2025. MarketsMOJO has given a 'Sell' call for the company's stock due to a decline in net sales by 26.67% year on year. Investors should carefully consider the company's financial standing before making any investment decisions.

MarketsMOJO has downgraded Beryl Drugs to a 'Sell' due to weak long-term fundamentals, slow growth in net sales and operating profit, and a high debt to EBITDA ratio. However, the stock is currently in a mildly bullish range and has attractive valuations. Non-institutional investors hold the majority of shares and the stock has outperformed BSE 500 in the last 3 years, 1 year, and 3 months.

Beryl Drugs, a microcap pharmaceutical company, has received a 'Hold' rating from MarketsMOJO due to its attractive valuation and strong market performance. However, its profits have declined and it has weak fundamental strengths, such as a low ROCE and slow growth. The stock has outperformed BSE 500 in the last 3 years, 1 year, and 3 months.

Beryl Drugs, a microcap pharmaceutical company, has been downgraded to 'Sell' by MarketsMOJO due to weak fundamental strength, poor growth, and high debt. Recent results show a decline in net sales, but the stock is still attractive in terms of valuation. Despite past returns, profits have fallen and majority of shareholders are non-institutional.

Beryl Drugs, a microcap pharmaceutical company, has reached a 52-week high on October 8th, 2024, with a stock price of Rs. 46. It has outperformed the sector by 9.94% and has gained after two consecutive days of falling. The company's stock is currently trading higher than its moving averages, indicating a positive trend. Beryl Drugs has shown a remarkable growth of 96.63% in the past year, showcasing its potential in the pharmaceutical industry. Despite its small size, the company has caught the attention of investors.

Beryl Drugs, a microcap pharmaceutical company, has been making headlines as its stock price reached a 52-week high on September 9th, 2024. The stock has gained 38.37% in 5 days and is currently trading higher than its moving averages. It has also outperformed the market, making it a promising company in the pharmaceutical industry.

Beryl Drugs, a microcap pharmaceutical company, has received a 'Hold' rating from MarketsMOJO on September 6th, 2024. The stock's technical indicators suggest a bullish trend, with factors such as MACD, Bollinger Band, KST, and OBV showing positive signals. However, its weak long-term fundamentals and recent decline in profits should also be considered before investing.

Beryl Drugs, a microcap pharmaceutical company, has reported a flat performance in the last quarter with a slight improvement in its overall score. However, its net sales have decreased by 33.43% in the half-yearly period, raising concerns. The company remains optimistic about its future and is investing in research and development to expand its product portfolio. Investors are advised to carefully consider the current financial situation before making any investment decisions.

Beryl Drugs, a microcap pharmaceutical company, has been downgraded to 'Sell' by MarketsMOJO due to weak long-term fundamentals, low growth in net sales and operating profit, and a high debt to EBITDA ratio. However, the stock is currently trading at a discount and has shown strong market performance, making it an attractive investment option.

Beryl Drugs, a microcap pharmaceutical company, has received an upgraded stock call from MarketsMOJO to a 'Hold' rating. The technical trend has improved and the stock is currently trading at a discount with a return of 152.86% in the past year. However, weak fundamental strengths and high debt may be areas of concern for investors.

Beryl Drugs, a microcap pharmaceutical company, has been downgraded to 'Sell' by MarketsMOJO due to weak long-term fundamentals, low growth, and high debt. However, the stock has multiple bullish indicators and an attractive valuation. Non-institutional investors hold majority shares, potentially leading to volatility. Despite this, the company has shown strong performance in the past year.

Beryl Drugs, a microcap pharmaceutical company, has received a 'Hold' rating from MarketsMOJO due to its positive technical indicators and attractive valuation. The stock has shown a return of 134.99% in the past year and has a potential undervaluation according to its PEG ratio. However, its weak long-term fundamentals and recent decline in net sales should be considered before investing.

Beryl Drugs, a microcap pharmaceutical company, has been downgraded to a 'Sell' by MarketsMOJO due to weak long-term performance, low growth in net sales and operating profit, and a high debt to EBITDA ratio. Despite some bullish indicators, the stock is currently trading at a discount and has a majority of non-institutional shareholders. Investors should carefully consider these factors before making any investment decisions.

Beryl Drugs, a microcap pharmaceutical company, has received a 'Hold' rating from MarketsMOJO due to its bullish trend and attractive valuation. With a return of 148.28% and a PEG ratio of 0, the stock is undervalued. However, non-institutional shareholders and weak long-term fundamentals pose potential risks. Investors should conduct their own research before making any decisions.

Beryl Drugs, a microcap pharmaceutical company, has been downgraded to a 'Sell' by MarketsMOJO due to weak long-term fundamental strength, poor growth in net sales and operating profit, and a high debt to EBITDA ratio. Despite positive technical indicators, the stock may be overvalued and investors should approach with caution.

Beryl Drugs, a microcap pharmaceutical company, has received a 'Hold' rating from MarketsMOJO based on technical indicators and strong returns of 177.03% in the past year. However, weak long-term fundamentals and a decline in net sales in the latest quarter may raise concerns for investors.

Beryl Drugs, a microcap pharmaceutical company, has been downgraded to 'Sell' by MarketsMOJO due to weak long-term fundamentals, including low ROCE, poor growth, and high debt. Despite some bullish indicators, recent results and shareholder makeup suggest caution for potential investors.

Beryl Drugs, a microcap pharmaceutical company, has received a 'Hold' rating from MarketsMOJO on April 5, 2024. The company has shown strong performance in the past year with a return of 186.48% and an increase in profits by 94%. However, its long-term fundamental strength and high debt to EBITDA ratio may be areas of concern for investors.